drugset

drugset / Trial / NCT05861128

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

NCT05861128 ↗

Phase 3 Unknown 258 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

Timeline

Start: 2023-11-10
Primary completion: 2025-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jaktinib	Unknown	100 mg	Oral

Indications